Incidence, resource use and costs associated with postherpetic neuralgia: A population-based retrospective study;Incidencia, uso de recursos y costes asociados a la neuralgia postherpética: Estudio retrospectivo de base poblacional

Revista de Neurologia

Volumn 55, Issue 8, 2012, Pages 449-461

  Sicras Mainar, Antonio ^a   Navarro Artieda, Ruth ^b   Ibáñez Nolla, Jordi ^c   Pérez Ronco, Julián ^d,e  

^a Dirección de Planificación y Desarrollo Organizativo   (Spain)

^b Dirección Médica Fresenius Medical Care   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d SA ^*

^e GRÜNENTHAL GMBH   (Germany)

Author keywords

Health costs; Herpes zoster; Postherpetic neuralgia; Resource use

Indexed keywords

ADULT; AGE; ANALYSIS OF COVARIANCE; COMORBIDITY; CONFIDENCE INTERVAL; DEMENTIA; DEMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; POPULATION RESEARCH; POSTHERPETIC NEURALGIA; PRIMARY HEALTH CARE; PRODUCTIVITY; PSYCHOSIS; REVIEW; RISK; STATISTICAL SIGNIFICANCE;

EID: 84867885162     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5508.2012298     Document Type: Review

References (47)

1. IASP Task Force in Taxonomy. Pain terms: a current list with definitions and notes on usage. In Merksey H, Bogduk N, eds. Classification of chronic pain syndromes and definitions of pain terms. 2 ed. Seattle: IASP Press; 1994. p. 206-13.
2. Fishbain DA, Lewis JE, Cutler R, Cole B, Rosomoff HL, Rosomoff RS. Can the neuropathic pain scale discriminate between non-neuropathic and neuropathic pain? Pain Med 2008; 9: 149-60.
3. Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med 2011; 123: 134-42.
4. Galluzzi KE. Managing herpes zoster and postherpetic neuralgia. J Am Osteopath Assoc 2009; 109 (Suppl 2): S7-12.
5. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008; 8: 45-56.
6. Opstelten W, Mauritz JW, De Wit NJ, Van Wijck AJ, Stalman WA, Van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002; 19: 471-5.
7. Plaghki L, Adriaensen H, Morlion B, Lossignol D, Devulder J. Systematic overview of the pharmacological management of postherpetic neuralgia. An evaluation of the clinical value of critically selected drug treatments based on efficacy and safety outcomes from randomized controlled studies. Dermatology 2004; 208: 206-16.
8. Johnson RW, Wasner G, Saddier P, Baron R. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25: 991-1006.
9. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13: 327-31.
10. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Invest 2010; 30: 765-76.
11. Raja SN, Haythornwaite JA, Papagallo M, Clark MR, Travison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59: 1015-21.
12. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003: 104: 323-31.
13. Armstrong EP, Malone DC, McCarberg B, Panarites CJ, Pham SV. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin 2011; 27: 939-50.
14. Clère F, Delorme-Morin C, George B, Navez M, Rioult B, Tiberghien-Chatelain F, et al. 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France. Drugs Aging 2011; 28: 693-702.
15. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; 2: CD006866.
16. Chen N, Yang M, He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2010; 12: CD005582.
17. Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2011; 3: CD007795.
18. Mick G, Gallais JL, Simon F, Pinchinat S, Bloch K, Beillat M, et al. Burden of herpes zoster and postherpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over. Rev Epidemiol Sante Publique 2010; 58: 393-401.
19. Smith KJ, Roberts MS. Sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis. J Pain 2007; 8: 396-404.
20. Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010; 10: 230.
21. Gálvez R, Rejas J, Pérez M, Gómez M. Prevalencia del dolor neuropático en España: implicaciones clínicas, laborales y asistenciales. Med Clin (Barc) 2005; 125: 221-9.
22. Montero-Homs J, Gutiérrez-Rivas E, Pardo-Fernández J, Navarro-Darder C. Estudio de prevalencia, incidencia y caracterización del dolor neuropático en consultas de neurología. Estudio PREVADOL. Neurologia 2005; 20: 385-91.
23. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005; 30: 374-85.
24. Cebrián-Cuenca AM, Díez-Domingo J, San Martín-Rodríguez M, Puig-Barberá J, Navarro-Pérez J. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian Community of Spain. BMC Infect Dis 2011; 11: 302.
25. Lamberts H, Wood M, Hofmans-Okkes IM, eds. The International Classification of Primary Care in the European Community. With a multi-language layer. Oxford: Oxford University Press; 1993.
26. Guidelines for ATC classification. Oslo: Nordic Collaborating Centre for Drug Statistics Methodology; 1991.
27. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
28. Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991: 29: 452-72.
29. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197-200.
30. de la Gómez CA. Scientific evidence based medicine: myth and reality of variability in clinical practice and its impact on health outcomes. An Sist Sanit Navar 2003; 26: 11-26.
31. Bowsher D. The management of postherpetic neuralgia. Postgrad Med J 1997; 73: 623-9.
32. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321: 794-6.
33. Watson P. Postherpetic neuralgia. Am Fam Physician 2011; 84: 690-2.
34. Dworkin RH. Inadequate evidence for a revised definition of postherpetic neuralgia. Pain 2007; 128: 189-90.
35. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24: 1308-14.
36. Gautier A, Breuer J, Carrington D, Martin M, Rèmy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137: 38-47.
37. Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med 2011; 123: 134-42.
38. McCarberg B. Managing the comorbidities of postherpetic neuralgia. J Am Acad Nurse Pract 2003; 15 (Suppl 12): S16-21.
39. Katz J, McDermott MP, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. J Pain 2005; 6: 782-90.
40. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545-51.
41. Lancaster T, Silagy C, Gray S. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract 1995; 45: 39-45.
42. Alper B, Lewis P. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? A systematic review of the literature. J Fam Pract 2000; 49: 255-64.
43. Edmunds J, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19: 3076-90.
44. Davies L, Cossins L, Bowsher D, Drummond M. The cost of treatment for postherpetic neuralgia in the UK. Pharmacoeconomics 1994; 6: 142-8.
45. Yawn B, Itzler R, Wolan P, Pellissier J, Sy L, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc 2009; 84: 787-94.
46. Schieber GJ, Poullier JP. International health care spending. Health Aff (Millwood) 1986; 5: 111-22.
47. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, et al; EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13: 1153-69.